

UNITED STATES PATENT AND TRADEMARK OFFICE
BEFORE THE PATENT TRIAL AND APPEAL BOARD

**SAMSUNG ELECTRONICS CO., LTD.,
SAMSUNG ELECTRONICS AMERICA, INC.,
FOSSIL GROUP, INC.,
FOSSIL STORES I, INC.,
FOSSIL PARTNERS, L.P.,
OURA HEALTH OY, AND
ONEPLUS TECHNOLOGY (SHENZHEN) CO., LTD.**

Petitioners,

v.

OMNI MEDSCI, INC.,

Patent Owner.

Case IPR2025-01254
Patent No. 12,268,475

**PETITIONERS' RANKING AND EXPLANATION OF PARALLEL
PETITIONS**

1. Petitioners Samsung Electronics Co. Ltd., Samsung Electronics America Inc., Fossil Group, Inc., Fossil Stores I, Inc., Fossil Partners, L.P., Oura Health Oy, and OnePlus Technology (Shenzhen) Co., Ltd. (“Petitioners”) have filed two petitions for review of claims 1, 5-8, and 11-13 of U.S. Patent No. Patent No. 12,268,475 (the “’475 patent”): (1) a petition for *inter partes* review (IPR2025-01254, the “IPR Petition”) and (2) a petition for post grant review (PGR2025-00063, the “PGR Petition”), and submit this explanation of the differences between the petitions and a ranking of the petitions for the Board’s consideration.

2. Because the ’475 patent issued on April 8, 2025, less than 9 months ago, whether Petitioners may challenge the patentability of the ’475 patent in a post grant review or an *inter partes* review depends on whether the ’475 patent is considered an AIA patent or not. *See* 35 U.S.C. §§ 311(c), 321(c).

3. Omni Medsci, Inc. (“Patent Owner”) asserts in a co-pending civil action¹ that the ’475 patent is at least entitled to a priority date of December 31, 2012. Ex.1022, 8-9. For the purposes of both Petitions, Petitioners do not contest Patent Owner’s assertion of the ’475 patent’s December 31, 2012 priority date. Therefore, by Patent Owner’s own admission, the ’475 patent is not subject to the

¹ *Omni Medsci, Inc. v. Samsung Electronics Co., Ltd. et al.*, 2:24-cv-01070-JGR-RSP (E.D. Tex) (“Texas Case”).

AIA, and is available for *inter partes* review under 37 C.F.R. § 42.102(a)(2).

4. However, if Patent Owner later argues and/or the Board concludes that the '475 patent is not subject to the AIA, the '475 patent is instead available for post grant review. Thus, Petitioners have filed the conditional PGR Petition concurrently with the IPR Petition.

5. Petitioners' concurrent IPR and PGR Petitions are necessary to ensure that Petitioners' patentability challenges are heard by the Board in a timely manner regardless of whether the '475 patent is an AIA patent or not. Because the two petitions challenge the same claims based on the same obviousness grounds, are substantively duplicative, and only one would need to be instituted depending upon the Board's determination of the '475 patent's priority date,² they create no "substantial and unnecessary burden on the Board and the patent owner" or "fairness, timing, and efficiency concerns." See Consolidated Trial Practice Guide (Nov. 2019) at 59, available at <https://www.uspto.gov/sites/default/files/documents/tpgnov.pdf>.

² Because the '475 patent would not be eligible for simultaneous post-grant review and *inter partes* review proceedings, the Board need not institute review in both proceedings. See, e.g., *Trend Micro Inc., v. Cupp Computing As*, PGR2021-00101, Paper 16 at 6 (PTAB, Jan. 19, 2022) (denying PGR petition that was "substantively duplicative" of IPR petition and filed "out of an abundance of caution" due to questions regarding the challenged patent's AIA status).

I. Ranking

6. For the purposes of the IPR and PGR Petitions, Petitioners do not contest Patent Owner's representation in the Texas Case that the '475 patent has a priority date of December 31, 2012 and thus is not an AIA patent. Petitioners accordingly request that the Board institute *inter partes* review in IPR2025-01254 and moot post-grant review in PGR2025-00063.

7. Alternatively, if the Board determines that the '475 patent is an AIA patent and thus denies the petition in IPR2025-01254, Petitioners request that the Board institute post-grant review in PGR2025-00063 because the Petitioners are filing the PGR within nine months of the '475 patent's issue date of April 8, 2025.

'475 Patent	IPR Petition IPR2025-01254	PGR Petition PGR2025-00063
Challenged Claims	1, 5-8, and 11-13	1, 5-8, and 11-13
Number of Grounds	8	8
Ranking	#1	#2

II. Differences Between Petitions

8. Both IPR and PGR Petitions advance the same 35 U.S.C. § 103 invalidity grounds against the same challenged claims of the '475 patent and are substantively duplicative.

* * *

9. For these reasons set forth above, Petitioners respectfully request that the Board institute *inter partes* review in IPR2025-01254. Otherwise, the Board

should institute post-grant review in PGR2025-00063.

Dated: August 5, 2025

Respectfully submitted,

By: /James L. Davis, Jr./

Name: James L. Davis, Jr.

Registration No. 57,325

ROPES & GRAY LLP

Lead Counsel for Petitioners

CERTIFICATE OF SERVICE

The undersigned certifies service pursuant to 37 C.F.R. §§ 42.6(e) and 42.105(b) on the Patent Owner by FedEx of a copy of this Petitioners' Ranking and Explanation of Parallel Petitions at the correspondence address of record for the '475 patent:

109543 - Brooks, Kushman P.C./Cheetah Omni MedSci
150 W 2nd St., Suite 400N
Royal Oak, MI 48067
UNITED STATES

A courtesy copy was also sent via electronic mail to Patent Owner's litigation counsel at the following addresses:

William E. Davis III
bdavis@davisfirm.com
DAVIS FIRM, PC

Daniel S. Stringfield
dstringfield@nixonpeabody.com
Timothy P. Maloney
tmaloney@nixonpeabody.com
Daniel D. Georgiev
dgeorgiev@nixonpeabody.com
Peter Krusiewicz
pkrusiewicz@nixonpeabody.com
NIXON PEABODY LLP

Corey T. Leggett
cleggett@nixonpeabody.com
NIXON PEABODY LLP

Elizabeth M. Chiaviello
echiaviello@nixonpeabody.com
Benjamin R. Holt
bholt@nixonpeabody.com
NIXON PEABODY LLP

Dated: August 5, 2025

By: /James L. Davis, Jr./
Name: James L. Davis, Jr.
Registration No. 57,325
Lead Counsel for Petitioners